Previous 10 | Next 10 |
LAUSANNE, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced its Co-Founder and CEO Andrea Pfeifer has been awarded by the Swiss Eco...
LAUSANNE, Switzerland, Sept. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in the following upcoming virtual investor...
The broader markets hovered near the flat line throughout Tuesday's trading, eventually finishing with fractional losses. But that doesn't mean the day lacked excitement. Chinese video game stocks, for example, capped off a dramatic couple of days, bouncing back on Tuesday following a sharp d...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “AC Immune SA Rises 70% on Alzheimer’s Drug Trial Results” AC Immune SA (NASDAQ: ACIU) surged over 70% in premarket trading after announcing the first positi...
Gainers: Regional Health Properties (NYSE:RHE) +55%. AC Immune (NASDAQ:ACIU) +34%. Net Element (NASDAQ:NETE) +27%. Vallon Pharmaceuticals (NASDAQ:VLON) +25%. Spok (NASDAQ:SPOK) +23%. Elys Game Technology (NASDAQ:ELYS) +21%. Youdao (NYSE:DAO) +20%. Qualigen Therapeutics (NASDAQ:QLGN) +18%. Azu...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Virgin Galactic (NYSE: SPCE ) stock is soaring higher on Tuesday after Jefferies analyst Greg Konrad initiated coverage of the company. Source: Christopher Penler / Shutterstock.com Konrad kicked off the firm&...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips AC Immune (NASDAQ: ACIU ) stock is rising higher on Tuesday after revealing positive results from an Alzheimer’s disease study. Source: pathdoc / Shutterstock.com The study, which is being conducted by...
AC Immune SA (NASDAQ:ACIU) traded at a new 52-week high today of $12.58. Approximately 9.2 million shares have changed hands today, as compared to an average 30-day volume of 162,000 shares. AC Immune SA (NASDAQ:ACIU) is currently priced 39.4% above its average consensus analyst price ta...
Gainers: Regional Health Properties (NYSE:RHE) +53%, AC Immune (NASDAQ:ACIU) +39%, Regencell Bioscience (NASDAQ:RGC) +29%, Qualigen Therapeutics (NASDAQ:QLGN) +19%, Reneo Pharmaceuticals (NASDAQ:RPHM) +17%. Losers: RenovoRx (NASDAQ:RNXT) -21%, ...
Shares of AC Immune (NASDAQ: ACIU) , a clinical-stage biopharmaceutical company, are exploding higher in response to clinical trial results. Investors excited about the company's Alzheimer's disease candidate drove the stock 50.1% higher as of 10:35 a.m. EDT on Tuesday. AC Immun...
News, Short Squeeze, Breakout and More Instantly...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...
2024-05-30 18:00:07 ET Thomas Shrader from BTIG issued a price target of $8.00 for ACIU on 2024-05-30 16:49:00. The adjusted price target was set to $8.00. At the time of the announcement, ACIU was trading at $3.97. The overall price target consensus is at $10.00 with hi...